Macmillan Cancer Support has cited “soaring” pressures on the NHS, leaving staff table to provide the appropriate care for patients.
News
‘Fake news’ could worsen infectious disease ‘epidemic’
The information is as relevant than ever, with Coronavirus still spreading globally.
Subcutaneous Entyvio hits Crohn’s primary endpoint, misses secondary
If approved, the drug could have huge benefits for patients as they could self-administer their therapy from home.
‘Innovative’ PKU treatment launched in UK
PKU is a rare, inherited metabolic disorder that affects approximately 70 babies each year in the UK.
Interim data shows Stelara promise in Crohn’s
Interim data from the Phase IIIb STARDUST study showed that 79% of patients with moderately to severely active Crohn’s disease (CD) achieved clinical response and 67% were in clinical remission.
Mumps at ‘decade high’ in England
Many of the cases in 2019 were seen in the so-called ‘Wakefield cohorts’ – young adults born in the late nineties and early 2000s who missed out on the MMR vaccine when they were children.
Verona publishes Phase II COPD results
Ensifentrine showed clinically and statistically significant improvements in lung function at all doses.
NICE recommends wireless device for overactive bladder
The device has potential to save the NHS around £6,200 per patient assuming a 15-year life span.
‘Lack of skills and distrust’ preventing patients from using internet
A “lack of skills and a distrust of health information online” are two of the biggest barriers keeping patients from using the internet.
Keytruda hits endpoints in triple-negative breast cancer
Earlier this week, NICE released a draft guidance rejecting Keytruda when used in combo with Pfizer’s Inlyta (axitinib) to treat advanced renal cell carcinoma.
Another mid-late stage Alzheimer’s flop, this time for Lilly
Earlier this month, Roche also announced a gantenerumab Alzheimer’s failure, and last year Biogen and Eisai stopped two global Phase III trials of aducanumab.
UK cancer patients able to ‘visualise’ treatment effects
The GenesisCare technology is part of a £20m investment.
New study reiterates benefits of stopping smoking at ‘any age’
More than nine out of every 10 lung cells in current smokers have up to 10,000 extra genetic changes compared to non-smokers.
Novartis’ investigational capmatinib granted FDA priority
If approved, it will become the first therapy to specifically target METex14 mutated advanced lung cancer, a type of lung cancer with a particularly poor prognosis.
NICE refuses Keytruda, Inlyta cancer combo
Despite evidence suggesting that the Keytruda combo would be welcomed by patients, NICE cites uncertainty around the long-term benefit.
